Aleksandar Danilovski is Chief Scientific Officer (CSO) at Xellia Pharmaceuticals, Denmark, a specialty pharmaceutical company focused on anti-infective treatments against serious and life-threatening infections. He is also a member of the Scientific Selection Board of Novo Holdings’ REPAIR Impact Fund and a Board member of Active Biotech AB, Sweden and Pharmaero ApS, Denmark.
Aleksandar has participated in and led the development of several novel and patented specialty pharmaceutical products including more than 100 different drug substances. He is an inventor of more than 20 different patent families with granted worldwide patents and has authored numerous papers in peer-reviewed scientific journals. He has previously been the Head of European R&D for Barr Laboratories, Inc. and a member of the management board of PLIVA Pharmaceuticals. He has also been a member of the board of Rudgjer Boskovic Innovation.
Aleksandar received his PhD in Chemistry from the University of Cambridge, UK and received his bachelor’s degree from the University of Zagreb, Croatia